🚀 VC round data is live in beta, check it out!
Corvus Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Corvus Pharma and similar public comparables like Cohance Lifesciences, Lepu Biopharma, Zenas BioPharma, Taysha GTx and more.
Corvus Pharma Overview
About Corvus Pharma
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Founded
2014
HQ
Employees
31
Website
Sectors
Financials (LTM)
EV
$1B
Corvus Pharma Financials
Corvus Pharma reported last 12-month revenue of —.
In the same LTM period, Corvus Pharma generated — in gross profit and had net loss of ($29M).
Revenue (LTM)
Corvus Pharma P&L
In the most recent fiscal year, Corvus Pharma reported revenue of — and EBITDA of ($43M).
Corvus Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($43M) | XXX | XXX | XXX |
| Net Profit | ($29M) | XXX | ($15M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Corvus Pharma Stock Performance
Corvus Pharma has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Corvus Pharma's stock price is $15.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 5.0% | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCorvus Pharma Valuation Multiples
Corvus Pharma trades at (29.4x) EV/EBITDA.
EV / Revenue (LTM)
Corvus Pharma Financial Valuation Multiples
As of April 11, 2026, Corvus Pharma has market cap of $1B and EV of $1B.
Equity research analysts estimate Corvus Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corvus Pharma has a P/E ratio of (45.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (29.4x) | XXX | XXX | XXX |
| EV/EBIT | (25.4x) | XXX | (29.4x) | XXX | XXX | XXX |
| P/E | (45.5x) | XXX | (86.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (38.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Corvus Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Corvus Pharma Margins & Growth Rates
Corvus Pharma's revenue in the last fiscal year grew by —.
Corvus Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.4M for the same period.
Corvus Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Corvus Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Zenas BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Taysha GTx | XXX | XXX | XXX | XXX | XXX | XXX |
| TOWA Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corvus Pharma M&A Activity
Corvus Pharma acquired XXX companies to date.
Last acquisition by Corvus Pharma was on XXXXXXXX, XXXXX. Corvus Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Corvus Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCorvus Pharma Investment Activity
Corvus Pharma invested in XXX companies to date.
Corvus Pharma made its latest investment on XXXXXXXX, XXXXX. Corvus Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Corvus Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Corvus Pharma
| When was Corvus Pharma founded? | Corvus Pharma was founded in 2014. |
| Where is Corvus Pharma headquartered? | Corvus Pharma is headquartered in United States. |
| How many employees does Corvus Pharma have? | As of today, Corvus Pharma has over 31 employees. |
| Who is the CEO of Corvus Pharma? | Corvus Pharma's CEO is Richard A. Miller. |
| Is Corvus Pharma publicly listed? | Yes, Corvus Pharma is a public company listed on Nasdaq. |
| What is the stock symbol of Corvus Pharma? | Corvus Pharma trades under CRVS ticker. |
| When did Corvus Pharma go public? | Corvus Pharma went public in 2016. |
| Who are competitors of Corvus Pharma? | Corvus Pharma main competitors are Cohance Lifesciences, Lepu Biopharma, Zenas BioPharma, Taysha GTx. |
| What is the current market cap of Corvus Pharma? | Corvus Pharma's current market cap is $1B. |
| Is Corvus Pharma profitable? | No, Corvus Pharma is not profitable. |
| What is the current net income of Corvus Pharma? | Corvus Pharma's last 12 months net income is ($29M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.